Noltec
(Ilaprazole)Phase 3Small molecule
Ilaprazole is used to treat conditions caused by excess stomach acid, such as acid reflux and peptic ulcers. It works by reducing the amount of acid your stomach produces.[1] Noltec is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Noltec is one of 41 small molecule programs targeting Gastroesophageal Reflux Disease. It is currently in Phase 3.
2
Indications
24
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
28 competitors in Peptic Ulcer
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Bayer Aspirin
BayerApproved
Protonix
WWyeth-Lederle Vaccines
Approved
Cytotec
PfizerApproved
Dexilant
TakedaApproved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Aciphex
Akero TherapeuticsApproved
Zantac 150
CChattem
Approved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Duodenal Ulcer4 trials
Peptic ulcer3 trials
Drug Interactions3 trials
Gastroesophageal Reflux Disease2 trials
11 more indications
GastroIntestinal Bleeding1 trial
Prospective1 trial
Efficacy and Safety1 trial
Treatment1 trial
Helicobacter Pylori Infection1 trial
Pilot Study1 trial
Esophagitis1 trial
Helicobacter Pylori1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ilaprazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Potassium-Transporting Atpase Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLivzon Pharmaceutical Group Inc.